(BPT) – A rare disease is a disease, disorder, illness or condition that affects fewer than 200,000 Americans. 1 Since rare diseases impact a small number of people, they often remain relatively ...
DENVER — Four studies presented at the American Academy of Neurology annual meeting show improvements in patients with spinocerebellar ataxia who take troriluzole. “SCAs [spinocerebellar ataxias] are, ...
Cure Rare Disease (CRD), a clinical-stage nonprofit biotechnology company developing genetic medicines for ultra-rare and rare conditions, today announced that the U.S. Food and Drug Administration ...
Spinocerebellar ataxias are a group of neurodegenerative diseases characterized by the degeneration of Purkinje cells, a major class of neurons in the cerebellum. The resulting cerebellar dysfunction ...
- Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. - Troriluzole has been granted Fast-Track, Orphan Drug Designation (ODD) and ...
European Commission approves OMP Designation for NLX-112 (befiradol) following compelling results in studies funded by the US Dept of Defense. This OMP designation is a milestone for Neurolixis as we ...
A new study finds enhanced activity of a specific enzyme drives spinocerebellar ataxia type 14, which suggests inhibiting the enzyme may have therapeutic potential. pinocerebellar ataxias are a group ...
The FDA has issued a CRL to Biohaven regarding the NDA for troriluzole for the treatment of adults with spinocerebellar ataxia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback